Tumor Growth
Survival
Onvansertib + Zytiga® (abiraterone) demonstrates synergy in mCRPC model (C4-2)1
Onvansertib + Zytiga® (abiraterone) significantly increase mitotic arrest1
Phase 2 open-label trial (NCT03414034)
Adding onvansertib to daily Zytiga® to overcome resistance, extend treatment response and overall survival.
Phase 1b/2 open-label trial (NCT03829410)
Combining onvansertib with FOLFIRI/Avastin® to improve efficacy by increasing duration of response and overall survival.
Phase 1b/2 open-label trial (NCT03303339)
Combining onvansertib with decitabine to provide a new treatment option to improve efficacy and increase overalll survival.